Complement testing in the clinical laboratory

References

• Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014;32:433–459.
   PubMed Web of Science ®Google Scholar
• Nilsson B, Nilsson Ekdahl K. The tick-over theory revisited: is C3 a contact-activated protein? Immunobiology. 2012;217(11):1106–1110.
   PubMed Web of Science ®Google Scholar
• Lachmann PJ. Looking back on the alternative complement pathway. Immunobiology. 2018;223(8–9):519–523.
   PubMed Web of Science ®Google Scholar
• Maillard N, Wyatt RJ, Julian BA, et al. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol. 2015;26(7):1503–1512.
   PubMed Web of Science ®Google Scholar
• Schroder-Braunstein J, Kirschfink M. Complement deficiencies and dysregulation: pathophysiological consequences, modern analysis, and clinical management. Mol Immunol. 2019;114:299–311.
   PubMed Web of Science ®Google Scholar
• Mollnes TE, Jokiranta TS, Truedsson L, et al. Complement analysis in the 21st century. Mol Immunol. 2007;44(16):3838–3849.
   PubMed Web of Science ®Google Scholar
• Mollnes TE, Garred P, Bergseth G. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol. 1988;73(3):484–488.
   PubMed Web of Science ®Google Scholar
• Lachmann PJ. Preparing serum for functional complement assays. J Immunol Methods. 2010;352(1–2):195–197.
   PubMed Web of Science ®Google Scholar
• Yang S, McGookey M, Wang Y, et al. Effect of blood sampling, processing, and storage on the measurement of complement activation biomarkers. Am J Clin Pathol. 2015;143(4):558–565.
   PubMed Web of Science ®Google Scholar
• Ekdahl KN, Persson B, Mohlin C, et al. Interpretation of serological complement biomarkers in disease. Front Immunol. 2018;9:2237.
   PubMed Web of Science ®Google Scholar
• Prohaszka Z, Nilsson B, Frazer-Abel A, et al. Complement analysis 2016: clinical indications, laboratory diagnostics and quality control. Immunobiology. 2016;221(11):1247–1258.
   PubMed Web of Science ®Google Scholar
• Nilsson B, Ekdahl KN. Complement diagnostics: concepts, indications, and practical guidelines. Clin Dev Immunol. 2012;2012:962702.
   PubMedGoogle Scholar
• Gaya da Costa M, Poppelaars F, van Kooten C, et al. Age and sex-associated changes of complement activity and complement levels in a healthy caucasian population. Front Immunol. 2018;9:2664.
   PubMed Web of Science ®Google Scholar
• Nauta T. Chelating agents. In: Smith J, editor. Food additive user’s handbook. Boston (MA): Springer; 1991.
   Google Scholar
• Mejia-Vilet JM, Gomez-Ruiz IA, Cruz C, et al. Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis. Clin Rheumatol. 2020.
   Web of Science ®Google Scholar
• Laskowski J, Philbrook HT, Parikh CR, et al. Urine complement activation fragments are increased in patients with kidney injury after cardiac surgery. Am J Physiol Renal Physiol. 2019;317(3):F650.
   PubMed Web of Science ®Google Scholar
• Burwick RM, Fichorova RN, Dawood HY, et al. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension. 2013;62(6):1040–1045.
   PubMed Web of Science ®Google Scholar
• Mayer MM. On the destruction of erythrocytes and other cells by antibody and complement. Cancer Res. 1961;21:1262–1269.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Kubotsu K, Kida M, et al. Automated homogeneous liposome-based assay system for total complement activity. Clin Chem. 1995;41(4):586–590.
   PubMed Web of Science ®Google Scholar
• Seelen MA, Roos A, Wieslander J, et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods. 2005;296(1–2):187–198.
   PubMed Web of Science ®Google Scholar
• Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol Immunol. 2007;44(16):3875–3888.
   PubMed Web of Science ®Google Scholar
• WIESLAB®. Complement system screen package insert. Malmö (Sweden): WIESLAB; 2018.
   Google Scholar
• Ziccardi RJ, Cooper NR. Development of an immunochemical test to assess C1 inactivator function in human serum and its use for the diagnosis of hereditary angioedema. Clin Immunol Immunopathol. 1980;15(3):465–471.
   PubMedGoogle Scholar
• Li HH, Busse P, Lumry WR, et al. Comparison of chromogenic and ELISA functional C1 inhibitor tests in diagnosing hereditary angioedema. J Allergy Clin Immunol Pract. 2015;3(2):200–205.
   PubMed Web of Science ®Google Scholar
• Ward G, Simpson A, Boscato L, et al. The investigation of interferences in immunoassay. Clin Biochem. 2017;50(18):1306–1311.
   PubMed Web of Science ®Google Scholar
• Manzi S, Navratil JS, Ruffing MJ, et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum. 2004;50(11):3596–3604.
   PubMed Web of Science ®Google Scholar
• Rondelli T, Risitano AM, Peffault de Latour R, et al. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica. 2014;99(2):262–266.
   PubMed Web of Science ®Google Scholar
• Kirschfink M, Mollnes TE. Modern complement analysis. Clin Diagn Lab Immunol. 2003;10(6):982–989.
   PubMedGoogle Scholar
• Nilsson PH, Thomas AM, Bergseth G, et al. Eculizumab-C5 complexes express a C5a neoepitope in vivo: consequences for interpretation of patient complement analyses. Mol Immunol. 2017;89:111–114.
   PubMed Web of Science ®Google Scholar
• Dragon-Durey MA, Blanc C, Marinozzi MC, et al. Autoantibodies against complement components and functional consequences. Mol Immunol. 2013;56(3):213–221.
   PubMed Web of Science ®Google Scholar
• Hauer JJ, Shao D, Zhang Y, et al. Factor B and C4b2a autoantibodies in C3 glomerulopathy. Front Immunol. 2019;10:668.
   PubMed Web of Science ®Google Scholar
• Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy – understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019;15(3):129–143.
   PubMed Web of Science ®Google Scholar
• Mahler M, van Schaarenburg RA, Trouw LA. Anti-C1q autoantibodies, novel tests, and clinical consequences. Front Immunol. 2013;4:117.
   PubMed Web of Science ®Google Scholar
• Maloney BE, Perera KD, Saunders DRD, et al. Interactions of viruses and the humoral innate immune response. Clin Immunol. 2020;212:108351.
   PubMed Web of Science ®Google Scholar
• Sanchez-Corral P, Pouw RB, Lopez-Trascasa M, et al. Self-damage caused by dysregulation of the complement alternative pathway: relevance of the factor H protein family. Front Immunol. 2018;9:1607.
   PubMed Web of Science ®Google Scholar
• Jozsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008;111(3):1512–1514.
   PubMed Web of Science ®Google Scholar
• Holmes LV, Strain L, Staniforth SJ, et al. Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32. PLoS One. 2013;8(4):e60352.
   PubMed Web of Science ®Google Scholar
• Sinha A, Gulati A, Saini S, et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int. 2014;85(5):1151–1160.
   PubMed Web of Science ®Google Scholar
• Durey MA, Sinha A, Togarsimalemath SK, et al. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol. 2016;12(9):563–578.
   PubMed Web of Science ®Google Scholar
• Moore I, Strain L, Pappworth I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115(2):379–387.
   PubMed Web of Science ®Google Scholar
• Liaskos C, Rentouli S, Simopoulou T, et al. Anti-C1q autoantibodies are frequently detected in patients with systemic sclerosis associated with pulmonary fibrosis. Br J Dermatol. 2019;181(1):138–146.
   PubMed Web of Science ®Google Scholar
• Castelli R, Deliliers DL, Zingale LC, et al. Lymphoproliferative disease and acquired C1 inhibitor deficiency. Haematologica. 2007;92(5):716–718.
   PubMed Web of Science ®Google Scholar
• Vasil V, Vasilev MR, Valentin J, Lazarov,   et al. Autoantibodies against C3b - functional consequences and disease relavence. Front Immunol. 2019;10:64.
   PubMed Web of Science ®Google Scholar
• Corvillo F, Okroj M, Nozal P, et al. Nephritic factors: an overview of classification, diagnostic tools and clinical associations. Front Immunol. 2019;10:886.
   PubMed Web of Science ®Google Scholar
• Pangburn MK, Muller-Eberhard HJ. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem J. 1986;235(3):723–730.
   PubMed Web of Science ®Google Scholar
• Sarkar E, Roberts EG, Wallage MJ, et al. A simple immunofixation test for induced C3 degradation in disease states (including C3 nephritic factor) and its correlation with kidney biopsy. J Immunol Methods. 2014;402(1–2):71–75.
   PubMed Web of Science ®Google Scholar
• Paixao-Cavalcante D, Lopez-Trascasa M, Skattum L, et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int. 2012;82(10):1084–1092.
   PubMed Web of Science ®Google Scholar
• Rother U. A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. J Immunol Methods. 1982;51(1):101–107.
   PubMed Web of Science ®Google Scholar
• Chinn IK, Chan AY, Chen K, et al. Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: a working group report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2020;145(1):46–69.
   PubMed Web of Science ®Google Scholar
• Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15(9):733–747.
   PubMed Web of Science ®Google Scholar
• Wang H, Nettleton D, Ying K. Copy number variation detection using next generation sequencing read counts. BMC Bioinformatics. 2014;15:109.
   PubMed Web of Science ®Google Scholar
• Stuppia L, Antonucci I, Palka G, et al. Use of the MLPA assay in the molecular diagnosis of gene copy number alterations in human genetic diseases. Int J Mol Sci. 2012;13(3):3245–3276.
   PubMed Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–423.
   PubMed Web of Science ®Google Scholar
• Sridharan M, Kluge ML, Go RS, et al. Challenges in classification of novel CFH variants in patients with atypical hemolytic uremic syndrome. Thrombosis Update. 2020;1:100002.
   Google Scholar
• Ozen A, Comrie WA, Ardy RC, et al. CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis. N Engl J Med. 2017;377(1):52–61.
   PubMed Web of Science ®Google Scholar
• Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804–2811.
   PubMed Web of Science ®Google Scholar
• Jozsi M, Tortajada A, Uzonyi B, et al. Factor H-related proteins determine complement-activating surfaces. Trends Immunol. 2015;36(6):374–384.
   PubMed Web of Science ®Google Scholar
• Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet. 2010;376(9743):794–801.
   PubMed Web of Science ®Google Scholar
• McCluskey R. Diagnostic immunopathology. 2nd ed. New York (NY): Raven Press; 1995.
   Google Scholar
• Troxell ML, Lanciault C. Practical applications in immunohistochemistry: evaluation of rejection and infection in organ transplantation. Arch Pathol Lab Med. 2016;140(9):910–925.
   PubMed Web of Science ®Google Scholar
• Ardissino G, Tel F, Sgarbanti M, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Pediatr Nephrol. 2018;33(3):457–461.
   PubMed Web of Science ®Google Scholar
• Volokhina EB, van de Kar NC, Bergseth G, et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol. 2015;160(2):237–243.
   PubMed Web of Science ®Google Scholar
• Willrich MAV, Andreguetto BD, Sridharan M, et al. The impact of eculizumab on routine complement assays. J Immunol Methods. 2018;460:63–71.
   PubMed Web of Science ®Google Scholar
• Brodszki N, Frazer-Abel A, Grumach AS, et al. European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: deficiencies, diagnosis, and management. J Clin Immunol. 2020;40(4):576–591.
   PubMed Web of Science ®Google Scholar
• Heitzeneder S, Seidel M, Forster-Waldl E, et al. Mannan-binding lectin deficiency - good news, bad news, doesn’t matter? Clin Immunol. 2012;143(1):22–38.
   PubMed Web of Science ®Google Scholar
• Garred P, Genster N, Pilely K, et al. A journey through the lectin pathway of complement-MBL and beyond. Immunol Rev. 2016;274(1):74–97.
   PubMed Web of Science ®Google Scholar
• Gaya da Costa M, Poppelaars F, Berger SP, et al. The lectin pathway in renal disease: old concept and new insights. Nephrol Dial Transplant. 2018;33(12):2073–2079.
   PubMed Web of Science ®Google Scholar
• Howard M, Farrar CA, Sacks SH. Structural and functional diversity of collectins and ficolins and their relationship to disease. Semin Immunopathol. 2018;40(1):75–85.
   PubMed Web of Science ®Google Scholar
• Kilpatrick DC. Mannan-binding lectin: clinical significance and applications. Biochim Biophys Acta. 2002;1572(2–3):401–413.
   PubMed Web of Science ®Google Scholar
• Banerji A, Davis KH, Brown TM, et al. Patient-reported burden of hereditary angioedema: findings from a US patient survey. Ann Allergy Asthma Immunol. 2020;124(6):600–607.
   PubMed Web of Science ®Google Scholar
• Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602–616.
   PubMed Web of Science ®Google Scholar
• Bork K, Machnig T, Wulff K, et al. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J Rare Dis. 2020;15(1):289.
   PubMed Web of Science ®Google Scholar
• Frazer-Abel A, Sepiashvili L, Mbughuni MM, et al. Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation. Adv Clin Chem. 2016;77:1–75.
   PubMed Web of Science ®Google Scholar
• Syed YY. Lanadelumab: a review in hereditary angioedema. Drugs. 2019;79(16):1777–1784.
   PubMed Web of Science ®Google Scholar
• Nicola S, Rolla G, Brussino L. Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research. Drugs in Context. 2019;8:212605.
   PubMedGoogle Scholar
• Thurman JM, Frazer-Abel A, Holers VM. The evolving landscape for complement therapeutics in rheumatic and autoimmune diseases. Arthritis Rheumatol. 2017;69(11):2102–2113.
   PubMed Web of Science ®Google Scholar
• Pons-Estel GJ, Serrano R, Plasin MA, et al. Epidemiology and management of refractory lupus nephritis. Autoimmun Rev. 2011;10(11):655–663.
   PubMed Web of Science ®Google Scholar
• Fang QY, Yu F, Tan Y, et al. Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis. Nephrol Dialysis Transplant. 2008;24(1):172–178.
   PubMed Web of Science ®Google Scholar
• Troldborg A, Jensen L, Deleuran B, et al. The C3dg fragment of complement is superior to conventional C3 as a diagnostic biomarker in systemic lupus erythematosus. Front Immunol. 2018;9:581.
   PubMed Web of Science ®Google Scholar
• Kraaij T, Nilsson SC, van Kooten C, et al. Measuring plasma C4D to monitor immune complexes in lupus nephritis. Lupus Sci Med. 2019;6(1):e000326.
   PubMed Web of Science ®Google Scholar
• Hui-Yuen JS, Gartshteyn Y, Ma M, et al. Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity. Lupus. 2018;27(14):2262–2268.
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Chatham WW, Massarotti EM, et al. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum. 2012;64(12):4040–4047.
   PubMedGoogle Scholar
• Lonati PA, Scavone M, Gerosa M, et al. Blood cell-bound C4d as a marker of complement activation in patients with the antiphospholipid syndrome. Front Immunol. 2019;10:773.
   PubMed Web of Science ®Google Scholar
• OMIM [Internet]. Baltimore (MD): Johns Hopkins University; 2020 [cited 2020 Jun 1]. Available from: https://omim.org/phenotypicSeries/PS603075
   Google Scholar
• Lynch AM, Mandava N, Patnaik JL, et al. Systemic activation of the complement system in patients with advanced age-related macular degeneration. Eur J Ophthalmol. 2020;30(5):1061–1068.
   PubMed Web of Science ®Google Scholar
• Schick T, Steinhauer M, Aslanidis A, et al. Local complement activation in aqueous humor in patients with age-related macular degeneration. Eye. 2017;31(5):810–813.
   PubMed Web of Science ®Google Scholar
• Ricklin D, Barratt-Due A, Mollnes TE. Complement in clinical medicine: clinical trials, case reports and therapy monitoring. Mol Immunol. 2017;89:10–21.
   PubMed Web of Science ®Google Scholar
• Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019;18(9):707–729.
   PubMed Web of Science ®Google Scholar
• Ricklin D, Mastellos DC, Lambris JD. Therapeutic targeting of the complement system. Nat Rev Drug Discov. 2019.
   Google Scholar
• Barnett C, Tabasinejad R, Bril V. Current pharmacotherapeutic options for myasthenia gravis. Expert Opin Pharmacother. 2019;20(18):2295–2303.
   PubMed Web of Science ®Google Scholar
• Cai XJ, Li ZW, Xi JY, et al. Myasthenia gravis and specific immunotherapy: monoclonal antibodies. Ann NY Acad Sci. 2019;1452(1):18–33.
   PubMed Web of Science ®Google Scholar
• Chamberlain JL, Huda S, Whittam DH, et al. Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review. J Neurol. 2019.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15(2):113–124.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473–477.
   PubMed Web of Science ®Google Scholar
• Hinson SR, Roemer SF, Lucchinetti CF, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008;205(11):2473–2481.
   PubMed Web of Science ®Google Scholar
• Petzold A, Pittock S, Lennon V, et al. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry. 2010;81(1):109–111.
   PubMed Web of Science ®Google Scholar
• Veszeli N, Fust G, Csuka D, et al. A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission. Mol Immunol. 2014;57(2):200–209.
   PubMed Web of Science ®Google Scholar
• Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292–4295.
   PubMed Web of Science ®Google Scholar
• Sridharan M, Go RS, Willrich MAV. Atypical hemolytic uremic syndrome: review of clinical presentation, diagnosis and management. J Immunol Methods. 2018;461:15–22.
   PubMed Web of Science ®Google Scholar
• Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. CJASN. 2013;8(4):554–562.
   PubMed Web of Science ®Google Scholar
• Sansbury FH, Cordell HJ, Bingham C, et al. Factors determining penetrance in familial atypical haemolytic uraemic syndrome. J Med Genet. 2014;51(11):756–764.
   PubMed Web of Science ®Google Scholar
• Bu F, Borsa N, Gianluigi A, et al. Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Dev Immunol. 2012;2012:370426.
   PubMedGoogle Scholar
• Lemaire M, Fremeaux-Bacchi V, Schaefer F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45(5):531–536.
   PubMed Web of Science ®Google Scholar
• Ardissino G, Perrone M, Tel F, et al. Late onset cobalamin disorder and hemolytic uremic syndrome: a rare cause of nephrotic syndrome. Case Rep Pediatr. 2017;2017:2794060.
   PubMed Web of Science ®Google Scholar
• Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(4):345–357.
   PubMed Web of Science ®Google Scholar
• Osborne AJ, Breno M, Borsa NG, et al. Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy. J Immunol. 2018;200(7):2464–2478.
   PubMed Web of Science ®Google Scholar
• Challis RC, Ring T, Xu Y, et al. Thrombotic microangiopathy in inverted formin 2-mediated renal disease. J Am Soc Nephrol. 2017;28(4):1084–1091.
   PubMed Web of Science ®Google Scholar
• Bu F, Zhang Y, Wang K, et al. Genetic analysis of 400 patients refines understanding and implicates a new gene in atypical hemolytic uremic syndrome. JASN. 2018;29(12):2809–2819.
   Web of Science ®Google Scholar
• Sridharan M, Go RS, Abraham RS, et al. Diagnostic utility of complement serology for atypical hemolytic uremic syndrome. Mayo Clin Proc. 2018;93(10):1351–1362.
   PubMed Web of Science ®Google Scholar
• Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539–551.
   PubMed Web of Science ®Google Scholar
• George JN. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007. Kidney Int Suppl. 2009;75(112):S52–S54.
   Google Scholar
• Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323–335.
   PubMed Web of Science ®Google Scholar
• Go RS, Winters JL, Leung N, et al. Thrombotic microangiopathy care pathway: a consensus statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clin Proc. 2016;91(9):1189–1211.
   PubMed Web of Science ®Google Scholar
• Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15–39.
   PubMed Web of Science ®Google Scholar
• Le Quintrec M, Zuber J, Moulin B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13(3):663–675.
   PubMed Web of Science ®Google Scholar
• Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33(17–18):1389–1401.
   PubMed Web of Science ®Google Scholar
• Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256–1264.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Soliris product insert. Silver Springs (MD): US Department of Health and Human Services; 2017.
   Google Scholar
• Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018;13(4):e0195909.
   PubMed Web of Science ®Google Scholar
• McKeage K. Ravulizumab: first global approval. Drugs. 2019;79(3):347–352.
   PubMed Web of Science ®Google Scholar
• Roth A, Rottinghaus ST, Hill A, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Adv. 2018;2(17):2176–2185.
   PubMed Web of Science ®Google Scholar
• Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530–539.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540–549.
   PubMed Web of Science ®Google Scholar
• Connell NT. Ravulizumab: a complementary option for PNH. Blood. 2019;133(6):503–504.
   PubMed Web of Science ®Google Scholar
• Zipfel PF, Skerka C, Chen Q, et al. The role of complement in C3 glomerulopathy. Mol Immunol. 2015;67(1):21–30.
   PubMed Web of Science ®Google Scholar
• Pickering MC, D’Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84(6):1079–1089.
   PubMed Web of Science ®Google Scholar
• Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. 2012;81(5):434–441.
   PubMed Web of Science ®Google Scholar
• Servais A, Noel LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82(4):454–464.
   PubMed Web of Science ®Google Scholar
• Leung N, Drosou ME, Nasr SH. Dysproteinemias and glomerular disease. Clin J Am Soc Nephrol. 2018;13(1):128–139.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157.
   PubMedGoogle Scholar
• Brando B, Gatti A, Preijers F. Flow cytometric diagnosis of paroxysmal nocturnal hemoglobinuria: pearls and pitfalls - a critical review article. EJIFCC. 2019;30(4):355–370.
   PubMedGoogle Scholar
• Weitz IC, Razavi P, Rochanda L, et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res. 2012;130(3):361–368.
   PubMed Web of Science ®Google Scholar
• Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018;9(5):e01753.
   PubMed Web of Science ®Google Scholar
• Ip WK, Chan KH, Law HK, et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis. 2005;191(10):1697–1704.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhao G, Song N, et al. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7(1):77.
   PubMed Web of Science ®Google Scholar
• Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13.
   PubMed Web of Science ®Google Scholar
• Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370(7):632–639.
   PubMed Web of Science ®Google Scholar
• Passot C, Sberro-Soussan R, Bertrand D, et al. Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: lessons from a prospective multicentric study. Br J Clin Pharmacol. 2020. DOI:https://doi.org/10.1111/bcp.14627
   Google Scholar
• Ardissino G, Possenti I, Tel F, et al. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis. 2015;66(1):172–173.
   PubMed Web of Science ®Google Scholar
• Ardissino G, Testa S, Possenti I, et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014;64(4):633–637.
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Fila M, Provot F, et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. CJASN. 2017;12(1):50–59.
   PubMed Web of Science ®Google Scholar
• Volokhina E, Wijnsma K, van der Molen R, et al. Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment. Clin Pharmacol Ther. 2017;102(4):671–678.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Muus P, Roth A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62–73.
   PubMed Web of Science ®Google Scholar
• Cugno M, Gualtierotti R, Possenti I, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost. 2014;12(9):1440–1448.
   PubMed Web of Science ®Google Scholar
• Cataland S, Ariceta G, Chen P, et al. Discordance between free C5 and CH50 complement assays in measuring complement C5 inhibition in patients with aHUS treated with ravulizumab. Blood. 2019;134(1):1099.
   Google Scholar
• Wehling C, Amon O, Bommer M, et al. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol. 2017;187(2):304–315.
   PubMed Web of Science ®Google Scholar
• Willrich MAV, Ladwig PM, Martinez MA, et al. Monitoring ravulizumab effect on complement assays. J Immunol Methods. 2021;490:112944.
   PubMed Web of Science ®Google Scholar
• Ladwig PM, Barnidge DR, Willrich MA. Quantification of the IgG2/4 kappa monoclonal therapeutic eculizumab from serum using isotype specific affinity purification and microflow LC-ESI-Q-TOF mass spectrometry. J Am Soc Mass Spectrom. 2017;28(5):811–817.
   PubMed Web of Science ®Google Scholar
• Legendre CM, Licht C, Loirat C. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;369(14):1379–1380.
   PubMedGoogle Scholar
• Gavriilaki E, Yuan X, Ye Z, et al. Modified Ham test for atypical hemolytic uremic syndrome. Blood. 2015;125(23):3637–3646.
   PubMed Web of Science ®Google Scholar
• Noris M, Galbusera M, Gastoldi S, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014;124(11):1715–1726.
   PubMed Web of Science ®Google Scholar
• Oroszlan G, Kortvely E, Szakacs D, et al. MASP-1 and MASP-2 do not activate pro-factor D in resting human blood, whereas MASP-3 is a potential activator: kinetic analysis involving specific MASP-1 and MASP-2 inhibitors. J Immunol. 2016;196(2):857–865.
   PubMed Web of Science ®Google Scholar
• Merle NS, Church SE, Fremeaux-Bacchi V, et al. Complement system part I - molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.
   PubMed Web of Science ®Google Scholar